Abstract
The human papillomavirus (HPV) is one of the most common sexually transmitted infections and the etiologic agent of cervical dysplasia and cancer. Recent research on the safety and efficacy of prophylactic vaccines against HPV has shown promising results with nearly 100% efficacy in preventing persistent infections and cervical dysplasia. Several approaches are being tested in therapeutic vaccine clinical trials whereby E6, E7, or both agents are administered in live viral vectors, as proteins, or in nucleic acid form. Cell-based therapeutic vaccines are also being tested. HPV vaccines have the potential to eradicate a major cancer and source of morbidity around the world.
Article PDF
Similar content being viewed by others
References and Recommended Reading
Jemal A, Siegal R, Ward E, et al.: Cancer statistics. CA Cancer J Clin 2006, 56:106–130.
Jansen KU, Shaw AR: Human papillomavirus vaccines and prevention of cervical cancer. Annu Rev Med 2004, 55:319–331.
Spence A, Franco E, Ferenczy A: The role of human papillomaviruses in cancer: evidence to date. Am J Cancer 2005, 4:49–64.
Centers for Disease Control and Prevention: Genital HPV Infection—CDC Fact Sheet. Washington, DC: Centers for Disease Control and Prevention; 2004.
Bosch FX, de Sanjose S: HPVs and cervical cancer: burden and assessment of causality. J Natl Cancer Inst Monogr 2003, 31:3–13.
Trottier H, Franco EL: The epidemiology of genital human papillomavirus infection. Vaccine 2006 24(Suppl 1):S1-S15.
Richardson H, Kelsall H, Tellier P, et al.: The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev 2003:6:485–490.
Ho GY, Burk RD, Klein S, et al.: Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995, 87:1365–1371.
Breitburd F, Kirnbauer R, Hubbert NL, et al.: Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995, 69:3959–396.
Embers ME, Budgeon LR, Pickel M, et al.: Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein. J Virol 2002, 76:9798–9805.
Stanley M: Immune responses to human papillomavirus. Vaccine 2006, 24(Suppl):S16-S22. This article reviews the humoral and cell-mediated immune responses to HPV infection; their role in development of HPV vaccines is discussed.
Kirnbauer R, Booy F, Cheng: Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A 1992, 89:12180–12184.
Harper DM, Franco EL, Wheeler C, et al., and the GlaxoSmithKline HPV Vaccine Study Group: Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomized controlled trial. Lancet 2004, 364:1757–1765. This landmark study showed the safety and efficacy of HPV-16/18 L1 VLP vaccine in preventing cervical dysplasia and persistent HPV-16 and -18 infections.
Harper DM, Franco EL, Wheeler CM, et al.: HPV Vaccine Study group. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized control trial. Lancet 2006, 367:1247–1255. This follow-up study confirmed the sustained efficacy of HPV-16/18 L1 VLP vaccine in prevention of HPV16/18-related dysplasia and infection.
Dubin G, Colau B, Zahat T, et al.: Cross-protection against persistent HPV infection, abnormal cytology and CIN associated with HPV 16 and 18 related HPN types by a HPV 16/18 L1 VLP vaccine. Presented at the 22nd International Papilloma Conference. Vancouver, Canada. April–May 2005.
Villa LL, Costa RL, Petta CA, et al.: Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005, 6:271–278. This landmark study showed the safety and efficacy of quadrivalent HPV-6/11/16/18 L1 VLP vaccine in preventing cervical dysplasia and persistent HPV-6, -11, -16, and -18 infections.
Skjeldestad FE, et al.: Prophylactic quadrivalent human papillomavirus (HPV) (types 6, 11, 16, 18 L1 virus-like particle (VLP) vaccine (GardasilTM) reduces cervical intraepithelial neoplasia (CIN) 2/3 risk. Presented at the Infectious Disease Society of America 43rd Annual Meeting. San Francisco, CA. October 7, 2005; Abstract LB-8a. Available at http://www.idsociety.org/Template.cfm.
FDA licenses new vaccine for prevention of cervical cancer and other diseases in females caused by human papillomavirus. http://www.fda.gov/bbs/topics/ NEWS/2006/NEW01385.html
Kahn JA: Vaccination as a prevention strategy for human papillomavirus-related diseases [review]. J Adolesc Health 2005, 37:S10-S16.
Monk BJ, Wiley DJ: Will widespread human papillomavirus prophylactic vaccination change sexual practices of adolescent and young adult women in America? Obstet Gynecol 2006, 108:420–424. This article addresses the questions and concerns regarding the possible effect of prophylactic HPV vaccination on sexual practices of young women.
Frazer IH: Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol 2004, 4:46–54.
Padilla-Paz LA: Human papillomavirus vaccine: history, immunology, current status, and future prospects. Clin Obstet Gynecol 2005, 48:226–240. A comprehensive review of literature on prophylactic and therapeutic HPV vaccines.
Schreckenberger C, Kaufmann AM: Vaccination strategies for the treatment and prevention of cervical cancer. Curr Opin Oncol 2004, 16:485–491.
Daftarian P, Mansour M, Benoit AC, et al.: Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion. Vaccine 2006, 24:5235–5244.
Ahn WS, Bae SM, Kim TY, et al.: A therapy modality using recombinant IL-12 adenovirus plus E7 protein in a human papillomavirus 16 E6/E7-associated cervical cancer animal model. Hum Gene Ther 2003, 14:1389–1399.
Davidson EJ, Boswell CM, Sehr P, et al.: Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Res 2003, 63:6032–6041.
Garcia-Hernandez E, Gonzalez-Sanchez JL, Andrade-Manzano A, et al.: Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. Cancer Gene Ther 2006, 13:592–597.
Hussain SF, Paterson Y: What is needed for effective antitumor immunotherapy? Lessons learned using Listeria monocytogenes as a live vector for HPV-associated tumors. Cancer Immunol Immunother 2005, 54:577–586.
Sewell DA, Douven D, Pan ZK, et al.: Regression of HPV-positive tumors treated with a new Listeria monocytogenes vaccine. Arch Otolaryngol Head Neck Surg 2004, 130:92–97.
Bermudez-Humaran LG, Cortes-Perez NG, Le Loir Y, et al.: An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci. J Med Microbiol 2004, 53:427–433.
Muderspach L, Wilczynski S, Roman L et al.: A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res 2000, 6:3406–3416.
Goldstone S, Fife K, Fine P, et al.: Durable clearance of genital warts following HspE7 immunization. Presented at the International Human Papillomavirus Meeting. Paris, France; 2002.
Derkay CS, Arnold J, Bower C, et al.: HspE7 Treatment of pediatric recurrent respiratory papillomatosis (RRP): interim results utilizing a laryngeal staging and severity Scale (LSSS). Presented at meeting of the Society for Ear, Nose, and Throat Advances in Children; 2002.
Einstein MH, Kadish AS, Burk RD, et al.: Heat shock protein (HSP)-based immunotherapy (HspE7) for treatment of CIN III (NCI 5850, NYGOG). Presented at the Society of Gynecologic Oncologists meeting. Miami Beach, FL; 2005:74.
Garcia F, Petry KU, Muderspach L, et al.: ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2004, 103:317–326. This article discusses a therapeutic HPV vaccine with efficacy of greater than 60% in resolving high-grade cervical lesions.
Lin CT, Tsai YC, He L, et al.: A DNA vaccine encoding a codon-optimized human papillomavirus type 16 E6 gene enhances CTL response and anti-tumor activity. J Biomed Sci 2006, 13:481–488.
Banchereau J, Steinman RM: Dendritic cells and the control of immunity, Nature 1998, 392:245–252.
Schuler G, Steinman RM: Dendritic cells as adjuvants for immune-mediated resistance to tumors. J Exp Med 1996, 186:1183–1187.
Santin AD, Bellone S, Palmieri M, et al.: HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. Gynecol Oncol 2006, 100:469–78. These authors concluded that autologous DCs pulsed with HPV-16/18 E7 proteins could induce systemic B- and T-cell responses in cervical cancer patients who are unresponsive to standard treatment modalities.
Greenstone HL, Nieland JD, de Visser KE, et al.: Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc Natl Acad Sci U S A 1998, 95:1800–1805.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mahdavi, A., Monk, B.J. Recent advances in human papillomavirus vaccines. Curr Oncol Rep 8, 465–472 (2006). https://doi.org/10.1007/s11912-006-0076-7
Issue Date:
DOI: https://doi.org/10.1007/s11912-006-0076-7